What’s Going On With Novo Nordisk Stock Thursday? – Novo Nordisk (NYSE:NVO)
Oral Semaglutide Shows Superior Glycaemic Control The phase 3a study evaluated oral semaglutide in patients aged 10–17 years…
Novo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake – Eli Lilly (NYSE:LLY)
Early Prescription Trends Show Slower Start For Lilly Reuters, citing IQVIA data, reported that Eli Lilly recorded 1,390…
Novo Nordisk Sued Over Alleged Scheme To Delay Generic Victoza In Favor Of Ozempic – Novo Nordisk (NYSE:NVO)
Novo Nordisk A/S (NYSE:NVO) is accused of unlawfully extending its monopoly over its diabetes drug Victoza through a…
Eli Lilly’s Orforglipron Data Is Not Disastrous: Analyst – Eli Lilly (NYSE:LLY)
Eli Lilly and Co LLY released underwhelming data from a Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational…